The metabolic syndrome in women: Implications for therapy

International Journal of Clinical Practice, Supplement

Volumn , Issue 139, 2004, Pages 20-25

  Rosano, Giuseppe M C ^a   Vitale, Cristiana ^a   Silvestri, Antonello ^a   Fini, Massimo ^a  

^a Cardiovascular Research Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; METFORMIN; MOXONIDINE; ORAL ANTIDIABETIC AGENT; SEX HORMONE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE THERAPY; BLOOD CLOTTING; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; HYPERTENSION; LIPID METABOLISM; MENOPAUSE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT;

ADIPOSE TISSUE; ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR SYSTEM; FEMALE; GLUCOSE; HUMANS; HYPERTENSION; LIPIDS; MENOPAUSE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY;

EID: 1942466683     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-131.
2. Reaven G. Syndrome X: 10 years after. Drugs 1999; 58(Suppl 1): 19-20; discussion 75-82.
3. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88(6): 2404-2411.
4. Rosano GM, Fini M. Postmenopausal women and cardiovascular risk: impact of hormone replacement therapy. Cardiol Rev 2002; 10(1): 51-60.
5. Tchernof A, Poehlman ET, Despres JP. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab 2000; 26(1): 12-20.
6. Gambacciani M, Ciapponi M, Cappagli B et al. Climacteric modifications in body weight and fat tissue distribution. Climacteric 1999; 2(1): 37-44.
7. Wilson PW, D'Agostino RB, Sullivan L et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002; 162(16): 1867-1872.
8. Harris MM, Stevens J, Thomas N et al. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes Res 2000; 8(7): 516-524.
9. Walton C, Godsland IF, Proudler AJ et al. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese, healthy women. Eur J Clin Invest 1993; 23(8): 466-473.
10. Lindheim SR, Presser SC, Ditkoff EC et al. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 1993; 60(4): 664-647.
11. Ferrannini E, Natali A, Capaldo B et al. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 1997; 30(5): 1144-1149.
12. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992; 8(Suppl 1): 99-103.
13. de Aloysio D, Gambacciani M, Meschia M et al. The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 1999; 147: 147-153.
14. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-331.
15. Pansini F, Bonaccorsi G, Campobasso C et al. Influence of spontaneous and surgical menopause on atherogenic metabolic risk. Maturitas 1993; 17: 181-190.
16. Rosano GM, Patrizi R, Leonardo F et al. Effect of estrogen replacement therapy on heart rate variability and heart rate in healthy postmenopausal women. Am J Cardiol 1997; 80(6): 815-817.
17. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens 1997; 10(1): 77-83.
18. Tuomilehto J, Lindstrom J, Eriksson JG et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344(18): 1343-1350.
19. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1(2): 113-119.
20. Chrysant SG. The ALLHAT study: results and clinical implications. QJM 2003; 96(10): 771-773.
21. Practice Guidelines For Primary Care Physicians: 2003 ESH/ESC Hypertension Guidelines. J Hypertens 2003; 21(10): 1779-1786.
22. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999; 17(Suppl 3): S29-S35.
23. Kirch K, Hutt HJ, Planitz V. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. J Clin Pharmacol 1990; 30(12): 1088-1095.